Consensus Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-15 pm EDT			5-day change	1st Jan Change
41.55 ^USD	-0.46%		-1.63%	-17.87%

Apr. 11	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 10	Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	MT

Evolution of the average Target Price on Ionis Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

20bc24.xWnbKYs1Nikw4ksNpxzIOqt9z-M83dKqZ_bRJW-W4DQ.qyC9BONRZFhyl3t6yGiydPMQh7V9k6v9XpyJXV6kskGfLZBR-XBaRHyjIA~0988e102bcbe926ce29c5d98f1c62359

Analyst Recommendations on Ionis Pharmaceuticals, Inc.

Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	Apr. 10	MT
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating	Apr. 09	MT
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating	Mar. 06	MT
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	Feb. 26	MT
JPMorgan Chase Adjusts Price Target on Ionis Pharmaceuticals to $55 From $52, Maintains Neutral Rating	Feb. 01	MT
RBC Lifts Price Target on Ionis Pharmaceuticals to $70 From $65, Says Survey Suggests Wainua Launch May Surprise to Upside; Outperform Kept	Jan. 26	MT
Piper Sandler Adjusts Ionis Pharmaceuticals' Price Target to $62 From $60, Maintains Overweight Rating	Jan. 18	MT
BofA Securities Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $62 From $52	Jan. 02	MT
Stifel Adjusts Price Target on Ionis Pharmaceuticals to $50 From $45, Maintains Hold Rating	Dec. 18	MT
Goldman Sachs Raises Price Target on Ionis Pharmaceuticals to $28 From $25, Maintains Sell Rating	Nov. 03	MT
Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $48 From $45, Maintains Equalweight Rating	Nov. 03	MT
BofA Securities Upgrades Ionis Pharmaceuticals to Neutral From Underperform	23-10-23	MT
Raymond James Initiates Ionis Pharmaceuticals With Strong Buy Rating, Price Target is $63	23-09-29	MT
Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $45 From $42, Maintains Equalweight Rating	23-09-27	MT
Fed Rate Outlook Lifts Exchange-Traded Funds, Equity Futures Premarket Wednesday	23-08-09	MT
Citigroup Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $60 From $36	23-07-31	MT
Barclays Adjusts Price Target on Ionis Pharmaceuticals to $37 From $40, Maintains Equalweight Rating	23-05-04	MT
Citigroup Upgrades Ionis Pharmaceuticals to Neutral From Sell, Raises Price Target to $36 From $30	23-05-04	MT
Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $88 From $92, Maintains Overweight Rating	23-05-04	MT
Powell's mixed signals and Pacwest weigh on US indices	23-05-04
ANALYST RECOMMENDATIONS : AMD, Avis, Clorox, Flutter, Starbucks...	23-05-04
Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $42 From $40, Maintains Equalweight Rating	23-04-11	MT
Bernstein Initiates Ionis Pharmaceuticals at Underperform With $31 Price Target	23-03-21	MT
BMO Capital Trims Price Target on Ionis Pharmaceuticals to $67 From $70, Maintains Outperform Rating	23-02-23	MT
Barclays Adjusts Ionis Pharmaceuticals Price Target to $40 From $44, Maintains Equal Weight Rating	23-02-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

41.55 USD

Average target price

58.09 USD

Spread / Average Target

+39.81%

High Price Target

85 USD

Spread / Highest target

+104.57%

Low Price Target

29 USD

Spread / Lowest Target

-30.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ionis Pharmaceuticals, Inc.

Wolfe Research
Oppenheimer
JPMorgan Chase
RBC Capital Markets
Piper Sandler
BofA Securities
Stifel Nicolaus
Goldman Sachs
Morgan Stanley
Raymond James
Citigroup
Barclays
Wells Fargo Securities
Bernstein
BMO Capital
SVB Securities LLC
SVB Leerink
Guggenheim
William Blair & Co.
Needham & Co.
UBS
J.P. Morgan Chase

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar